March 2014 Issue of The Ophthalmologist

Our cataloging of the major eye diseases is insightful, even though impact factor analysis is flawed.

Mice that take exercise exhibit slower retinal degeneration than those that don’t. It could work for people too.

The finding that the core of the trabecular meshwork is an extension of Dua’s layer may have significance in understanding and treating glaucoma.

If you’re aged over 68 years, then statins significantly reduce your risk of developing AMD; it has no impact on younger age groups.

Previous studies linked aspirin use with age-related macular degeneration, but new data suggest otherwise: aspirin is innocent of all charges.

The new method to produce stem cells has run into difficulties in the form of image irregularities and the failure of other labs to reproduce the findings.

Vision training can restore some of the sight lost to glaucoma.

Acucela prices its initial public offering on the Tokyo Stock Exchange at $162M.

Aflibercept gets approved by NICE, STAAR’s Visian ICL with CentraFLOW gets approved in Japan, and rises and falls in Allergan and Alcon’s revenues.

If you’re a retina specialist, you’ll be more likely than not to see patients with diabetic macular edema (DME) on a daily basis. Lasers and anti-VEGF therapy have transformed outcomes within a generation

Although baby boomers may be in a state of denial regarding their own aging, ophthalmologists know differently. In particular, four diseases of the ageing eye comprise a demographic and economic timebomb.

For the sake of our patients and our profession, we need to improve upon the nineteenth-century pictograms that are currently used for visual assessment.

The Salzburg Reading Desk is one promising approach to standardizing visual assessments for multifocal intraocular lenses.

Advances in understanding of the therapeutic mechanisms that underpin micropulse laser treatment suggest that protocols for treatment of diabetic macular edema should be integrated.

Transforming complex, invasive and risky glaucoma surgery into a safe, elegant, and precise procedure.

Making an optimal eyedrop formulation has always been a major challenge; compromises had to be made. Nanodroplet emulsion technology has changed that. Here’s how.

What does analysis of the last five years of literature on glaucoma tell us about the priorities of the field and the major contributors to it?

To mark World Glaucoma Week, here are some of the many creative approaches being taken to communicate awareness of the disease around the world.

Attending conferences, making presentations and sitting on committees is part and parcel of the job for leading ophthalmologists. Here are my tips to make sure you arrive fresh and look the part.

Sitting down with Julia Haller, Ophthalmologist-in-Chief, and Joseph Bilson, Chief Executive Officer of the Wills Eye Hospital, Philadelphia, PA, USA.